BioXcel Therapeutics (BTAI) Competitors $5.24 +0.08 (+1.55%) Closing price 04:00 PM EasternExtended Trading$6.24 +1.01 (+19.18%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. CTOR, CLYM, ALTS, ACOG, IKT, CGEN, SCLX, FATE, PLX, and CHRSShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Citius Oncology (CTOR), Climb Bio (CLYM), ALT5 Sigma (ALTS), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), Compugen (CGEN), Scilex (SCLX), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors Citius Oncology Climb Bio ALT5 Sigma Alpha Cognition Inhibikase Therapeutics Compugen Scilex Fate Therapeutics Protalix BioTherapeutics Coherus Oncology BioXcel Therapeutics (NASDAQ:BTAI) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Is BTAI or CTOR more profitable? Citius Oncology has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -5,869.82%. BioXcel Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-5,869.82% N/A -134.45% Citius Oncology N/A -51.93%-22.17% Which has higher valuation & earnings, BTAI or CTOR? Citius Oncology has lower revenue, but higher earnings than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$868K87.88-$59.60M-$12.64-0.41Citius OncologyN/AN/AN/AN/AN/A Do analysts recommend BTAI or CTOR? BioXcel Therapeutics currently has a consensus price target of $39.75, suggesting a potential upside of 658.59%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 50.75%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer BTAI or CTOR? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Citius Oncology. MarketBeat recorded 5 mentions for BioXcel Therapeutics and 3 mentions for Citius Oncology. BioXcel Therapeutics' average media sentiment score of 0.46 beat Citius Oncology's score of 0.25 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, BTAI or CTOR? BioXcel Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BTAI or CTOR? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 4.6% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryBioXcel Therapeutics beats Citius Oncology on 9 of the 13 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.28M$3.08B$5.73B$9.76BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-0.4120.7830.3826.03Price / Sales87.88348.83428.56103.94Price / CashN/A43.2325.7828.79Price / Book-0.179.809.706.08Net Income-$59.60M-$54.08M$3.27B$265.64M7 Day Performance6.50%4.92%3.95%3.11%1 Month Performance189.50%3.64%3.81%0.39%1 Year Performance-53.69%8.20%31.26%18.52% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.5487 of 5 stars$5.24+1.6%$39.75+658.6%-52.5%$76.28M$868K-0.4190Gap DownCTORCitius Oncology1.338 of 5 stars$1.75+3.6%$3.00+71.4%+1.1%$132.45MN/A0.00N/ACLYMClimb Bio3.3077 of 5 stars$2.11+11.1%$9.00+326.5%N/A$128.75MN/A-3.019News CoverageGap UpHigh Trading VolumeALTSALT5 Sigma0.4018 of 5 stars$6.12+3.0%N/A+167.7%$128.36M$12.53M0.00170Gap UpACOGAlpha Cognition2.3271 of 5 stars$8.44+5.5%$20.00+137.0%N/A$128.16MN/A0.00N/AIKTInhibikase Therapeutics1.755 of 5 stars$1.72-1.7%$6.50+277.9%+23.1%$127.87MN/A-0.646News CoverageGap DownCGENCompugen2.252 of 5 stars$1.55+8.4%$4.00+158.1%-29.9%$127.61M$27.86M-7.0570Positive NewsHigh Trading VolumeSCLXScilex2.3775 of 5 stars$19.38+7.2%$455.00+2,247.8%-57.2%$125.76M$56.59M-0.6780FATEFate Therapeutics3.9457 of 5 stars$1.20+10.1%$3.58+198.6%-71.6%$125.71M$8.47M-0.83550PLXProtalix BioTherapeutics2.9904 of 5 stars$1.54+4.1%$15.00+874.0%+65.3%$122.60M$61.95M-11.85200Positive NewsGap UpCHRSCoherus Oncology4.2659 of 5 stars$1.07+1.9%$4.68+337.7%-15.8%$122.04M$266.96M0.69330News CoveragePositive News Related Companies and Tools Related Companies Citius Oncology Alternatives Climb Bio Alternatives ALT5 Sigma Alternatives Alpha Cognition Alternatives Inhibikase Therapeutics Alternatives Compugen Alternatives Scilex Alternatives Fate Therapeutics Alternatives Protalix BioTherapeutics Alternatives Coherus Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBREAKING: Meta, Apple and NASA rush to invest in new "E.I." techBig Tech and even NASA are racing to back a breakthrough known as “E.I. Tech,” set to launch September 1st. Ex...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access